NR'sThe 3 NR's from this past week show progress in locking down patents for Dermaprecise as well as showing the market that the injection device is getting closer to submission for FDA and CE Mark Approval, I would have thought that it would have spiked the share price a little with some reasonable volume but as usual that is not the case. We are basically up $.01 from the all-time low share price with minimal volume. It is hard to speculate what the management of the company thought would happen to the share price after releasing these NR's. I think they are always optomistic but I am sure disappointed. It looks like the only thing that will boost the share price is a judgement in favour of Replicel in the Shiseido Arbitration and the Dermaprecise FDA Approval application is submitted.
If both of these happen then we begin to guess as to what the affect will be on the share price.
A positive result from the arbitration could come in many forms and all will have a different affect on the share price. The best scenario is Shiseido is forced to compensate Replicel. The amount will have a direct correlation on the boost to the share price. Also if Replicel wins and Shiseido plans to press forward with bringing RCH-01 to market in Asia under a new arrangement with Replicel, Replicel's global potential for the product could be huge.
Once Dermaprecise is granted FDA Approval and eventually CE Mark Approval it will be interesting to see how the Dermal Industry adopts usage of the device. If the Industry enthusiastically buys the device we should should see a good bost to the share price.
O.K. now for the speculation on the share price if both of these above scenarios have a positve outcome. Without being too unrealistic I think the market cap could be $100,000,000 - $200,000,000 which would mean: $2.25 - $4.50.
Let's hope this happens.